Ngenla (somatrogon-ghla) Injection 24MG/72IU.

Description

Ngenla (somatrogon-ghla) is a cutting-edge, once-weekly, long-acting recombinant human growth hormone (rhGH) designed to treat pediatric patients with growth hormone deficiency (pGHD). Developed through advanced protein engineering, Ngenla offers an innovative approach to hormone replacement therapy, aiming to optimize clinical outcomes while reducing the burden of daily injections associated with traditional growth hormone treatments. Its unique molecular design, superior pharmacokinetic profile, and established efficacy make Ngenla a transformative choice for healthcare providers and families seeking better management options for children with GHD.

Mechanism of Action
Ngenla is a modified form of somatropin, the naturally occurring human growth hormone. Through recombinant DNA technology, somatrogon-ghla is engineered by fusing a single copy of the C-terminal peptide (CTP) from the beta subunit of human chorionic gonadotropin (hCG) to the amino acid sequence of somatropin. This strategic modification extends the circulating half-life of the molecule, allowing for once-weekly administration without compromising the biological activity of native growth hormone.

Upon administration, Ngenla binds to the growth hormone receptor (GHR) on target cells, activating the JAK-STAT signaling pathway. This stimulation results in the transcription of insulin-like growth factor-1 (IGF-1), which is crucial for promoting skeletal growth, cell proliferation, and metabolic regulation. Elevated and sustained IGF-1 levels support normal growth patterns in children with GHD.